Sildenafil treatment for portopulmonary hypertension

Reichenberger F., Voswinckel R., Steveling E., Enke B., Kreckel A., Olschewski H., Grimminger F., Seeger W., Ghofrani H. A.

Source: Eur Respir J 2006; 28: 563-567
Journal Issue: September
Disease area: Pulmonary vascular diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Reichenberger F., Voswinckel R., Steveling E., Enke B., Kreckel A., Olschewski H., Grimminger F., Seeger W., Ghofrani H. A.. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006; 28: 563-567

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Experience with inhaled iloprost and bosentan in portopulmonary hypertension
Source: Eur Respir J 2007; 30: 1096-1102
Year: 2007



Sildenafil treatment for portopulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 651s
Year: 2006

Inhaled iloprost for patients with portopulmonary hypertension
Source: Eur Respir J 2003; 22: Suppl. 45, 462s
Year: 2003

Iloprost treatment in portopulmonary hypertension
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008

Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2006 Oct 01;28(4):691-694
Year: 2006



Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension
Source: Eur Respir J 2002; 20: 339-343
Year: 2002



Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension
Source: Eur Respir J 2013; 41: 96-103
Year: 2013



Long-term treatment of pulmonary hypertension with aerosolized iloprost
Source: Eur Respir J 2001; 17: 8-13
Year: 2001



Acute effects of inhaled iloprost in portopulmonary hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 547s
Year: 2006

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
Source: Eur Respir J 2004; 24: 353-359
Year: 2004



Inhaled iloprost in HIV-related pulmonary arterial hypertension
Source: Eur Respir J 2004; 24: Suppl. 48, 109s
Year: 2004

Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension
Source: Eur Respir J 2007; 29: 469-475
Year: 2007



Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Source: Eur Respir J 2006; 28: 1195-1203
Year: 2006



Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension
Source: Eur Respir J 2015; 46: 405-413
Year: 2015



Sildenafil and aerolized iloprost treatment in two cases with primary pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 520s
Year: 2005

Inhaled iloprost for the treatment of pulmonary hypertension
Source: Eur Respir Rev 2009; 18: 29-34
Year: 2009


PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension
Source: Eur Respir J 2007; 29: 220-221
Year: 2007


Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 1354-1360
Year: 2009



Long-term outcome with intravenous iloprost in pulmonary arterial hypertension
Source: Eur Respir J 2009; 34: 132-137
Year: 2009



Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009